arrow
P

Pierre-Régis Burgel

assistance publique hopitaux paris (aphp)
H指数:61
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mucoactive therapies and the European Respiratory Society guideline for adult bronchiectasis: what now after the CLEAR trial?

黏液活性疗法与欧洲呼吸学会成人支气管扩张指南:CLEAR试验之后该怎么办?

2026-05-010
PRE
European Respiratory Society clinical practice guideline for the management of adult bronchiectasis

Chalmers, J.D.; Haworth, C.S.; Flume, P.; Long, M.B.; Burgel, P.R.; Dimakou, K.; Blasi, F.; Herrero-Cortina, B.; Dhar, R.; Chotirmall, S.H.; 等. 欧洲呼吸学会成人支气管扩张管理临床实践指南. Eur. Respir. J. 2025; 2501126, online ahead of print. [Google Scholar] [CrossRef]

2025-12-0122
PRE
Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) model

COPD急性加重的多维度预后风险分层:基线、严重程度和触发因素(BAt模型)

2025-11-250
PRE
Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates; Mortality; and Total Costs: PROMETHEUS France

单吸入器三联疗法使用增加对COPD急性加重率、死亡率及总成本的影响:PROMETHEUS France

2025-11-170
OAAI
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR

超越Trikafta:评估组织依赖性N1303K-CFTR挽救的新模型

2025-10-290
OAAI
Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor

CFTR变异体对伊莱克萨福特-替扎卡福特-伊卡福特的全球流行率

2025-10-170
OAAI
Pregnancy after lung transplantation: TRIGGER study on anti-human leucocyte antigen alloimmunization and antibody-mediated rejection risk

肺移植后的妊娠:TRIGGER研究——关于抗人白细胞抗原同种免疫和抗体介导的排斥反应风险

2025-10-080
PRE
Identification of structural predictors of lung function improvement in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor using deep-learning

使用深度学习识别接受elexacaftor-tezacaftor-ivacaftor治疗的囊性纤维化成人患者中肺功能改善的结构预测因子

2025-09-300
PRE
Sweat chloride and lung function responses to elexacaftor–tezacaftor–ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies

汗氯和肺功能对含elexacaftor–tezacaftor–ivacaftor的疗法在携带两种与一种应答型CFTR变异的囊性纤维化患者中的反应:两项真实世界观察性研究的分析

2025-09-030
PRE
Bronchiectasis in France: data on disease characteristics in 630 patients from the European Bronchiectasis registry (EMBARC)

支气管扩张症在法国:来自欧洲支气管扩张登记研究(EMBARC)的630例患者疾病特征数据

2025-09-010
OAAI
Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programme

伊拉斯卡弗特-替扎卡弗特-维扎卡弗特在携带两种CFTR Class I变异的囊性纤维化患者中的使用:来自法国同情用药计划的真实世界数据

2025-08-300
PREAI
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study

症状、未来急性加重的风险以及对长期大环内酯治疗的反应:一项观察性研究

2025-08-270
OAAI
Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor

接受elexacaftor-tezacaftor-ivacaftor治疗的囊性纤维化相关糖尿病成人患者中,胰岛素剂量调整后的糖化血红蛋白A1c水平降低。

2025-07-020
OAAI